Microcap Ledger Greenwich LifeSciences, Inc. $GLSI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Stafford, TX
- Fiscal year end
- December 31
- Shares outstanding
- 14,678,208 [10-Q 2026-08-11]
What the company doesAI summary of filing
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, a cancer immunotherapy combining a HER2/neu peptide (GP2) with an immunoadjuvant (GM-CSF), currently in Phase III trials for breast cancer. The company is evaluating GLSI-100 to prevent breast cancer recurrence in HER2/neu-positive patients who have completed standard trastuzumab-based therapy, with the Phase III trial (Flamingo-01) enrolling patients across U.S. and European sites. Greenwich LifeSciences is pre-revenue and has no manufacturing, sales, or marketing capabilities, relying on third-party manufacturers and contract research organizations. The company's commercial strategy, if approved, may involve strategic partners, distributors, or an internal sales force. [10-K 2026-06-01]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$9.61M | −$6.64M | $8.88M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | −$19.36M | −$9.91M | $6.18M | [10-K 2026-06-01] |
| FY ended Dec 2024 | — | −$17.41M | −$7.27M | $4.09M | [10-K 2026-06-01] |
- Quarterly cash burn
- −$3.32M
- Cash runway Estimate
- ~8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-08-02 | 13,144,653 | [10-Q 2024-08-14] |
| 2024-10-28 | 13,144,653 | [10-Q 2024-11-14] |
| 2025-04-11 | 13,273,539 | [10-K 2025-04-15] |
| 2025-05-09 | 13,368,304 | [10-Q 2025-05-20] |
| 2025-07-28 | 13,630,257 | [10-Q 2025-08-14] |
| 2025-10-28 | 13,854,539 | [10-Q 2025-11-14] |
| 2026-05-26 | 14,678,208 | [10-Q 2026-06-04] |
| 2026-07-24 | 14,678,208 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2024-10-07; declared effective 2024-10-17 [S-3 2024-10-07]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-29 | Patel Snehal | buy | 700 | $13.10 | [4 2026-07-30] |
| 2026-07-28 | Patel Snehal | buy | 1,500 | $13.59 | [4 2026-07-30] |
| 2026-07-27 | Patel Snehal | buy | 1,500 | $13.62 | [4 2026-07-29] |
| 2026-07-24 | Patel Snehal | buy | 1,100 | $12.88 | [4 2026-07-27] |
| 2026-07-23 | Patel Snehal | buy | 2,500 | $13.14 | [4 2026-07-27] |
| 2026-01-13 | Patel Snehal | buy | 1,800 | $29.83 | [4 2026-01-15] |
| 2026-01-12 | Patel Snehal | buy | 2,900 | $27.54 | [4 2026-01-14] |
| 2025-12-31 | Patel Snehal | buy | 4,300 | $21.36 | [4 2026-01-05] |
| 2025-12-30 | Patel Snehal | buy | 2,900 | $21.73 | [4 2026-01-02] |
| 2025-12-18 | Patel Snehal | buy | 4,100 | $12.62 | [4 2025-12-19] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-06-04 | 10-Q | Quarterly report |
| 2026-06-01 | 10-K | Annual report |
| 2026-03-31 | NT 10-K | Notice of late annual report |
| 2025-12-18 | 8-K | Shareholder vote results |
| 2025-11-14 | 10-Q | Quarterly report |
| 2025-11-03 | DEF 14A | Proxy statement |
Alerts for $GLSI
Email me when Greenwich LifeSciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.